KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
Revenue of KYORIN Holdings, Inc. (4569.T)
Revenue in 2023 (TTM): $771.12 M
According to KYORIN Holdings, Inc.'s latest financial reports the company's current revenue (TTM) is $771.12 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of KYORIN Holdings, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $771.12 M | $331.59 M | $66.42 M | $45.28 M | $34.33 M |
| 2022 | $730.73 M | $323.64 M | $57.81 M | $44.55 M | $30.47 M |
| 2021 | $680.82 M | $318.95 M | $56.24 M | $33.65 M | $25.37 M |
| 2020 | $663.85 M | $333.06 M | $60.25 M | $53.88 M | $39.55 M |
| 2019 | $709.52 M | $367.93 M | $69.1 M | $53.25 M | $39.67 M |
| 2018 | $732.98 M | $370.36 M | $76.77 M | $60.38 M | $44.31 M |
| 2017 | $713.76 M | $397.24 M | $80.33 M | $58.45 M | $42.41 M |
| 2016 | $744.29 M | $416.27 M | $90.52 M | $62.68 M | $47.13 M |
| 2015 | $770.81 M | $465.28 M | $150.74 M | $121.38 M | $87.99 M |
| 2014 | $729.76 M | $429.15 M | $114.77 M | $113.29 M | $77.83 M |
| 2013 | $718.66 M | $440.96 M | $134.35 M | $118.13 M | $77.58 M |
| 2012 | $690.48 M | $431.57 M | $138.75 M | $120.01 M | $80.14 M |
| 2011 | $665.97 M | $427.75 M | $114.96 M | $98.46 M | $59.55 M |
| 2010 | $671.37 M | $429.1 M | $128.11 M | $110.55 M | $70.49 M |
| 2009 | $643.6 M | $401.82 M | $111.3 M | $90.2 M | $57.08 M |
| 2008 | $586.34 M | $349 M | $58.22 M | $31.27 M | $13.14 M |
| 2007 | $523 M | $318.13 M | $67.38 M | $36.25 M | $14.12 M |
| 2006 | $497.34 M | $299.81 M | $84.28 M | $53.25 M | $31.24 M |
| 2005 | $477.74 M | $306.68 M | $78.38 M | $54.62 M | $33.73 M |
| 2004 | $427.69 M | $281.36 M | $67.65 M | $25.88 M | $12.99 M |